The purpose of this study is to assess the pharmacokinetics (PK), metabolite profile, routes and extent of elimination, mass balance, as well as safety and tolerability of \[14C\]BMS-986419 in healthy male participants.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
8
Specified dose on specified days
Labcorp Clinical Research Unit - Madison
Madison, Wisconsin, United States
Maximum observed plasma concentration (Cmax)
Time frame: Up to Day 20
Time of maximum plasma observed concentration (Tmax)
Time frame: Up to Day 20
Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC [0-T])
Time frame: Up to Day 20
Total radioactivity recovered in urine (UR)
Time frame: Up to Day 30
Total radioactivity recovered in feces (FR)
Time frame: Up to Day 30
Total radioactivity recovered in bile (BR)
Time frame: Up to Day 30
Total radioactivity recovered (Rtotal)
Time frame: Up to Day 30
Percent of total radioactivity recovered (%Total)
Time frame: Up to Day 30
Percent of total radioactivity recovered in urine (%UR)
Time frame: Up to Day 30
Percent of total radioactivity recovered in feces (%FR)
Time frame: Up to Day 30
Number of Participants with Adverse Events (AEs)
Time frame: Up to Day 60
Number of Participants with Serious AEs (SAEs)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Up to Day 60
Number of Participants with AEs leading to discontinuation
Time frame: Up to Day 60
Number of Participants with Vital Sign Abnormalities
Time frame: Up to Day 30
Number of Participants with Electrocardiogram (ECG) Abnormalities
Time frame: Up to Day 30
Number of Participants with Physical Examination Abnormalities
Time frame: Up to Day 30
Number of Participants with Clinical Laboratory Abnormalities
Time frame: Up to Day 30